8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 23, 2008

SCIVANTA MEDICAL CORPORATION

(Exact name of registrant as specified in charter)

Nevada	000-27119	22-2436721
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
215 Morris Avenue, Spring Lake, New Jersey		07762
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (732) 282-1620

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1 - Registrant’s Business and Operations

Item 1.01   Entry into a Material Definitive Agreement

On October 23, 2008, Scivanta Medical Corporation (the “Company”) and the Research Foundation of the State University of New York, for and on behalf of the University of Buffalo (the “Foundation”), and Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren, M.D., Ph.D. (“Lundgren”) entered into a Second Addendum to the Technology License Agreement dated November 10, 2006, as amended on June 29, 2007 (the “Technology License Agreement”). The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor.”

Pursuant to the Second Addendum to the Technology License Agreement, the Company will make a one-time cash payment to Hickey of $158,438 on the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology, but no later than December 31, 2009. In addition, the Company will not be required to make any of the milestone payments set forth in Section 3.5 of the Technology License Agreement. Further, the parties have agreed that the remaining amount of $108,235, which is due from the Company to the Licensor for the reimbursement of patent costs incurred by the Licensor prior to November 10, 2006, will be paid by the Company to the Licensor as follows: a) $39,101 will be paid in cash to Hickey on or before October 31, 2008; b) $34,567 will be paid in cash to Lundgren on or before October 31, 2008; and c) $34,567 will be paid in cash to Lundgren on or before February 1, 2009.

In conjunction with the Second Addendum to the Technology License Agreement, the Licensee shall issue 1,001,920 shares of its common stock, par value $0.001 per share (“Common Stock”), as follows: (a) 412,860 shares of Common Stock will be issued to the Foundation; (b) 162,500 shares of Common Stock will be issued to Hickey; and (c) 426,560 shares of Common Stock will be issued to Lundgren.

Section 9 - Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(d)Exhibits:

Exhibit
Number	Description
10.25	Second Addendum to the Technology License Agreement, dated November 10, 2006 and amended on June 29, 2007, among Scivanta Medical Corporation, The Research Foundation of State University of New York, for and on behalf of the University at Buffalo, Donald D. Hickey, M.D. and Clas E. Lundgren, M.D., Ph.D., dated October 23, 2008.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCIVANTA MEDICAL CORPORATION
(Registrant)
By:	/s/ David R. LaVance
	David R. LaVance
	Chairman of the Board, President and Chief Executive Officer

Date: October 28, 2008

3

EXHIBIT INDEX

Exhibit
Number	Description
10.25	Second Addendum to the Technology License Agreement, dated November 10, 2006 and amended on June 29, 2007, among Scivanta Medical Corporation, The Research Foundation of State University of New York, for and on behalf of the University at Buffalo, Donald D. Hickey, M.D. and Clas E. Lundgren, M.D., Ph.D., dated October 23, 2008.

EX-10.25

EXHIBIT 10.25

Second Addendum to the Technology License Agreement

between

The Research Foundation of State University of New York

for and on behalf of University at Buffalo

and

Donald D. Hickey, M.D.

and

Clas E. Lundgren, M.D., Ph.D.

and

Scivanta Medical Corporation

This Second Addendum (this “Second Addendum”) to the Technology License Agreement (as such term is defined below), entered into as of the 23rd day of October, 2008 (the “Second Addendum Effective Date”), is by and among The Research Foundation of State University of New York, for and on behalf of University at Buffalo, a non-profit corporation organized and existing under the laws of the State of New York (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren, M.D., Ph.D. (a/k/a Claes Lundgren and referenced herein as “Lundgren”) and Scivanta Medical Corporation (formerly Medi-Hut Co., Inc.), a corporation duly organized under the laws of the State of Nevada, and having its principal place of business at 215 Morris Avenue, Spring Lake, New Jersey 07762 (“Licensee”). Foundation, Hickey and Lundgren will be collectively referenced herein as “Licensor.” Capitalized terms used herein, but not otherwise defined herein, shall have such meanings as given to such terms in the Technology License Agreement.

WHEREAS, Licensor and Licensee entered into an exclusive Technology License Agreement on November 10, 2006, as amended on June 29, 2007 (the “Technology License Agreement”), to facilitate the development and commercialization of certain technology owned by Licensor so that this technology may be utilized to the fullest extent for the benefit of Licensee, Licensor, the inventor(s) and the public; and

WHEREAS, Licensor and Licensee desire to modify the aforementioned Technology License Agreement for the mutual benefit of both parties;

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

1. The modifications of the Technology License Agreement herein will be effective as of the Second Addendum Effective Date and will remain in effect for the duration of the Technology License Agreement unless further modified in writing by the parties hereto.

2. Section 3.5 of the Technology License Agreement is deleted in its entirety.

3. A new Section 3.10 is added to the Technology License Agreement as follows:

3.10Cash Payment. Licensee will pay Hickey a one-time cash payment of $158,438 on or before the date that is thirty (30) days after the first commercial sale of a Licensed Product by the Licensee. If the Licensee fails to make the full payment pursuant to this Section 3.10 on or before the due date, then interest shall accrue on any outstanding balance at a rate that is equal to the lesser of the maximum rate allowed by law or 1.5% per month, but in any case the cash payment and any accrued interest must be paid in full no later than December 31, 2009.

4. A new Section 3.11 is added to the Technology License Agreement as follows:

3.11Stock Grant. As of October 23, 2008, the Licensee shall issue 1,001,920 shares of its common stock, par value $0.001 per share (“Common Stock”), as follows: (a) 412,860 shares of Common Stock will be issued to the Foundation; (b) 162,500 shares of Common Stock will be issued to Hickey; and (c) 426,560 shares of Common Stock will be issued to Lundgren. Each certificate representing the shares of Common Stock to be issued pursuant to this Section 3.11 will contain a restrictive legend on transfer and the Licensee will have no obligation to register any of the shares of Common Stock under the Securities Act of 1933, as amended.

4. Section 6.1 of the Technology License Agreement will be deleted in its entirety and replaced with the following:

6.1 Patent Costs Incurred Pre-Effective Date. Licensee and Licensor agree that as of October 23, 2008 an aggregate of $120,900 has been paid by the Licensee to the Licensor as reimbursement of Patent Costs incurred by the Licensor prior to the Effective Date of the Technology License Agreement. The Licensee and Licensor further agree that as of October 23, 2008, the remaining amount due from the Licensee to the Licensor for reimbursement of Patent Costs incurred by the Licensor prior to the Effective Date of the Technology License Agreement is $108,235. This amount will be paid by the Licensee to the Licensor as follows: (a) $39,101 will be paid in cash to Hickey on or before October 31, 2008; (b) $34,567 will be paid in cash to Lundgren on or before October 31, 2008; and (c) $34,567 will be paid in cash to Lundgren on or before February 1, 2009.

5. Other than as specifically modified in this Second Addendum, all other terms, conditions and covenants of the Technology License Agreement shall remain in full force and effect.

2

IN WITNESS WHEREOF, the undersigned duly authorized representatives of the parties have executed this Second Addendum, effective as of the Second Addendum Effective Date.

SCIVANTA MEDICAL CORPORATION	THE RESEARCH FOUNDATION OF
	STATE UNIVERSITY OF
	NEW YORK
By:  /s/ David R. LaVance	By:  /s/ Woodrow W. Maggard
David R. LaVance	Woodrow W. Maggard
Title: President and Chief Executive Officer	Title: Associate Vice Provost, STOR
DONALD D. HICKEY, M.D.	CLAS E. LUNDGREN, M.D., Ph.D.
By:  /s/ Donald D. Hickey, M.D.	By:  /s/ Clas E. Lundgren, M.D., Ph.D.
Donald D. Hickey, M.D.	Clas E. Lundgren, M.D., Ph.D.

3